Medicaid now covers lung cancer biomarker testing for low-income patients

What it does

This bill requires state Medicaid programs to cover lung cancer biomarker testing—diagnostic tests that identify genetic or protein markers in tumors to guide treatment—starting January 1, 2027. The bill amends the Social Security Act to add biomarker testing to the list of mandatory Medicaid-covered services, ensuring eligible low-income patients can access these tests without cost-sharing.

Why we flagged it

The bill's sole operative mechanism is to add a specific diagnostic service to the mandatory benefits list under Medicaid, expanding coverage for a precision oncology test. This is a straightforward public-health entitlement expansion.

What the text implies

• States will bear increased Medicaid expenditures for biomarker testing; federal matching funds will offset some but not all costs, creating a potential budget pressure on state programs.
• The January 1, 2027 effective date gives states ~2 years to establish billing, coding, and reimbursement infrastructure; implementation delays could affect access in early 2027.
• Biomarker testing may increase demand for oncology services downstream (targeted therapies, specialist consultations), creating secondary cost pressures on Medicaid and the healthcare system.
• The bill does not specify reimbursement rates or which biomarker tests qualify, leaving CMS to define scope through regulation—implementation details will determine actual access and cost.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicaid beneficiaries gain access to a diagnostic service that can improve cancer treatment outcomes and reduce out-of-pocket costs. The mandate ensures equitable access across states and removes cost as a barrier to precision oncology testing for low-income patients.

Who stands to gain

• diagnostic laboratory companies (Guardant Health, Foundation Medicine, Myriad Genetics, etc.)
• hospital pathology departments
• oncology practices offering biomarker-guided treatment

Named in the bill

Medicaid, Social Security Act, CMS (Centers for Medicare & Medicaid Services), state Medicaid agencies, diagnostic laboratories, oncology providers

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Nov 28, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 28, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $190,000 in lobbying spend. A filing names 50 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Josh Gottheimer, the sponsor, reported $1,000,800 in PAC receipts in the 2026 cycle.

• American Lung Association — $190,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.